Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0153690 (
bone metastases
)
6,382
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bone-targeted therapies have been the choice of treatments for cancer metastases in bone to minimize skeletal morbidity and preserve patients' quality of life.
Rhein
is of particular interest due to its high bone affinity. Here we reported a novel
Rhein
- polyethylene glycol (PEG)-nano hydroxyapatite (nHA) conjugate to deliver doxorubicin (DOX) and Phosphorus-32 (
32
P) simultaneously for enhanced cancer chemo-radiotherapy. The synthetic
Rhein
-PEG-nHA conjugates were sphere in shape with an average diameter of ~120 nm. Their morphology, drug release and bone affinity were confirmed in vitro. The release profiles of DOX depend on pH condition, but
32
P exhibited good stability.
Rhein
-PEG-nHA also showed high bone affinity in vivo, and the tumor volume decreased after the DOX@Rhein-PEG-nHA and
32
P@Rhein-PEG-nHA treatments. Most importantly, the DOX/
32
P@Rhein-PEG-nHA showed the strongest inhibition on the growth of
bone metastases
of breast cancer. We revealed the potential of
Rhein
-PEG-nHA in combined chemo-radiation treatment for
bone metastases
of breast cancer.
...
PMID:Rhein-PEG-nHA conjugate as a bone targeted drug delivery vehicle for enhanced cancer chemoradiotherapy. 3227 33
